CNTB Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
169.0K
0
-100.0%
16.0K
-66.7%
48.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
169.0K
0
-100.0%
16.0K
-66.7%
48.0K
Operating Expenses
19.8M
+27.4%
15.5M
-12.2%
17.7M
+31.3%
13.5M
+17.7%
11.4M
R&D
15.0M
+33.2%
11.3M
+1.5%
11.1M
+26.6%
8.8M
+32.3%
6.6M
SG&A
4.7M
+11.8%
4.2M
-35.5%
6.6M
+40.1%
4.7M
-2.4%
4.8M
Operating Income
-19607000
-26.3%
-15526000
+12.2%
-17677000
-31.7%
-13424000
-17.3%
-11447000
EBITDA
-19443000
-26.7%
-15345000
+12.3%
-17498000
-31.7%
-13287000
-17.9%
-11274000
Net Income
-19398000
-28.4%
-15109000
+12.2%
-17200000
-33.3%
-12899000
-25.6%
-10272000
EPS (Basic)
$-0.34
-21.4%
$-0.28
+9.7%
$-0.31
-34.8%
$-0.23
-21.1%
$-0.19
EPS (Diluted)
$-0.34
-21.4%
$-0.28
+9.7%
$-0.31
-34.8%
$-0.23
-21.1%
$-0.19
Shares (Diluted)
56.5M
+0.8%
56.1M
+0.6%
55.7M
+0.4%
55.5M
+0.3%
55.4M
Connect Biopharma (CNTB) — Financials